---
title: "Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280335741.md"
description: "Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report"
datetime: "2026-03-24T14:35:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280335741.md)
  - [en](https://longbridge.com/en/news/280335741.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280335741.md)
---

# Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report

Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report

### Related Stocks

- [ATXS.US](https://longbridge.com/en/quote/ATXS.US.md)

## Related News & Research

- [‘Solve all diseases,’ you say?](https://longbridge.com/en/news/287121830.md)
- [Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit | WHWK Stock News](https://longbridge.com/en/news/287060019.md)
- [Medtronic plans to buy SPR Therapeutics for $650 million to expand pain treatment options](https://longbridge.com/en/news/287081570.md)
- [Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi Year Shareholder Returns](https://longbridge.com/en/news/287031171.md)
- [Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum | WHWK Stock News](https://longbridge.com/en/news/286560823.md)